1. Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study [version 2; peer review: 2 approved]
- Author
-
Mansoor Saleh, Reena Shah, Linda Moranga, Ann Karanu, Jasmit Shah, Viviane Oluoch, Henry Karanja, Alfred Mburu, Julius Mutiso, Peter Betti, Daisy Mugo, Zaitun Nneka, Abdirahman Issak Abdi, Wanzila Usyu Mutinda, George M.Warimwe, Lynette Isabella Ochola-Oyier, James Nyagwange, Yiakon Sein, Francis M. Ndungu, Bernadette Kutima, John N. Gitonga, Philip Bejon, Perpetual Wanjiku, Eunice W. Nduati, Jedidah Mwacharo, Kennedy Mwai, Shahin Sayed, and John Kimotho
- Subjects
COVID-19 ,SARS-CoV-2 ,natural infection ,binding-antibodies ,neutralizing antibodies ,kinetics ,eng ,Medicine ,Science - Abstract
Background Given the low levels of coronavirus disease 2019 (COVID-19) vaccine coverage in sub-Saharan Africa (sSA), despite high levels of natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) exposures, strategies for extending the breadth and longevity of naturally acquired immunity are warranted. Designing such strategies will require a good understanding of naturally acquired immunity. Methods We measured whole-spike immunoglobulin G (IgG) and spike-receptor binding domain (RBD) total immunoglobulins (Igs) on 585 plasma samples collected longitudinally over five successive time points within six months of COVID-19 diagnosis in 309 COVID-19 patients. We measured antibody-neutralising potency against the wild-type (Wuhan) SARS-CoV-2 pseudovirus in a subset of 51 patients over three successive time points. Binding and neutralising antibody levels and potencies were then tested for correlations with COVID-19 severities. Results Rates of seroconversion increased from day 0 (day of PCR testing) to day 180 (six months) (63.6% to 100 %) and (69.3 % to 97%) for anti-spike-IgG and anti-spike-RBD binding Igs, respectively. Levels of these binding antibodies peaked at day 28 (p0.99). Similarly, antibody-neutralising potencies peaked at day 28 (p0.60, p
- Published
- 2024
- Full Text
- View/download PDF